Kiniksa Pharmaceuticals Ltd expected to post a loss of 21 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

28/04/2023 19:32

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 1 (estimated). 
    * The Hamilton Bermuda-based   company is expected to report
 a
44.7% increase in revenue to $46.577 million from $32.19 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kiniksa
Pharmaceuticals
Ltd is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 4.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $21​, above​ its last closing price
of $10.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.23       -0.23      0.06      Beat    125.8
 Sep. 30 2022  0.79        0.78       3.18      Beat    306.4
 Jun. 30 2022  -0.45       -0.44      -0.29     Beat    34.5​
 Mar. 31 2022  -0.40       -0.41      -0.36     Beat    11.5
 ​​Dec.        -0.42       -0.42      -0.53     Missed  -26.2
 31 2021                                                
 Sep. 30 2021  -0.65       -0.65      -0.44     Beat    32​
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23
 Mar. 31 2021  -0.63       -0.72      -0.72     Met     0.7
 This summary was machine generated April 28 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated